Indonesian officers have threatened to “alter” insurance policies against Australia if the Morrison govt makes a decision to transport Australia’s embassy in Israel from Tel Aviv to Jerusalem. The warnings from officers within the Indonesian international ministry and ministry of defence – first reported via ABC’s AM – upload to a rising backlash from 13 …
Reported by The News Articles 1 hour ago.
Indonesia warns it will 'adjust' policies if Australia moves Israel embassy
↧
↧
NAB's Thorburn is 'ashamed' at the bank's conduct
National Australia Bank chief executive Andrew Thorburn said watching the royal commission this year had left him "disappointed" and "aggrieved".
Reported by Brisbane Times 58 minutes ago.
↧
Marsh brothers haven't stepped up: Warne
Shane Warne has labelled Shaun and Mitch Marsh’s recent form as “inconsistent” and “ordinary” as Australia face a heavy second Test defeat against Pakistan.
Reported by Brisbane Times 35 minutes ago.
↧
Royal tour: The one native Australian food Meghan Markle refused to eat during lunch in Melbourne
The Duke and Duchess of Sussex were taken inside the kitchen of Melbourne-based restaurant Charcoal Lane for a tasting of some of Australia's native cuisine. But Mehhan Markle didn't eat one thing.
Reported by MailOnline 35 minutes ago.
↧
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Asia-Pacific CRO Novotech has acquired Australasian specialist CRO Clinical Network Services (CNS), with a mutual mission to expand services
SYDNEY, Oct 19, 2018 - (ACN Newswire) - Novotech, the largest Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS), as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Both companies will continue to retain their separate brands and identities.
Early phase CNS clients, wishing to advance into later phase regional trials, can tap into Novotech's Asia-Pacific expertise backed by 10 partnership agreements with leading hospitals and medical institutions, offering access to 1.4 billion people living in urban areas across the region. Novotech has 400+ staff across Asia-Pacific and business development offices in the USA. CNS has more than 140 staff in Australia, New Zealand and the USA.
As part of the deal, clients can access leading services from both groups, including the CNS BioDesk, which provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech's advanced regional IT infrastructure, to support their clinical research programs.
Novotech CEO John Moller said:
"Biopharma clients should know this acquisition is a bringing together of the highest quality CROs in the region. Very importantly, we have developed remarkably similar company cultures, and I know the teams are excited about the opportunity of working together.
"Novotech and CNS will continue to operate under separate brands with CNS specialising in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specialising in regional Asia-Pacific and global project delivery across all phases.
"Our Asia-Pacific in-country relationships enable a comprehensive understanding of local regulatory requirements and changes, access to leading investigators, strong site connections, and accessible patient populations to deliver success for our clients within timelines and budgets."
CNS Managing Director Russ Neal commented:
"Early phase research in Australasia has seen incredible growth over the last 6-7 years and CNS is proud to be a significant part of this proven capability. As our clients have experienced success with us, we have often wished we had the international reach to continue supporting them.
"This truly complimentary association with Novotech now means that we are able to offer our clients access to Novotech's Asia-Pacific experience and expertise in later phase regional or global trials. On the other hand, Novotech clients can access our highly regarded global product development and regulatory affairs consultancy team, BioDesk, based out of Washington DC, London and Australia"
CNS COO and Executive Director Gabrielle McKee further added:
"CNS clients will also benefit from many of Novotech's strengths, including IT infrastructure and specialist functions such as legal, learning and development, marketing and analytics,. and particularly exciting, CNS and Novotech offer our clients one of the most experienced and knowledgeable biometrics teams in the region, with 70 staff in the combined unit."
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia-Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia-Pacific presence includes running clinical trials in all key regional markets, with a worldwide reach through the company's network of strategic partners.
About Clinical Network Services (CNS) - https://clinical.net.au/
Clinical Network Services (CNS) is an integrated service group focused on product development. Headquartered in Australia, with offices in New Zealand, the UK and the USA, CNS creates value for small to medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service, integrating BioDesk, an intelligent global product development and regulatory affairs consultancy, with its committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.
CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables it to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
Media Contact:
Susan Fitzpatrick-Napier
communications@novotech-cro.com
USA: +1 415 951 3228
AUS: +61 2 8218 2144
ASIA: +65 3159 3427Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 43 minutes ago.
SYDNEY, Oct 19, 2018 - (ACN Newswire) - Novotech, the largest Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS), as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Both companies will continue to retain their separate brands and identities.
Early phase CNS clients, wishing to advance into later phase regional trials, can tap into Novotech's Asia-Pacific expertise backed by 10 partnership agreements with leading hospitals and medical institutions, offering access to 1.4 billion people living in urban areas across the region. Novotech has 400+ staff across Asia-Pacific and business development offices in the USA. CNS has more than 140 staff in Australia, New Zealand and the USA.
As part of the deal, clients can access leading services from both groups, including the CNS BioDesk, which provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech's advanced regional IT infrastructure, to support their clinical research programs.
Novotech CEO John Moller said:
"Biopharma clients should know this acquisition is a bringing together of the highest quality CROs in the region. Very importantly, we have developed remarkably similar company cultures, and I know the teams are excited about the opportunity of working together.
"Novotech and CNS will continue to operate under separate brands with CNS specialising in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specialising in regional Asia-Pacific and global project delivery across all phases.
"Our Asia-Pacific in-country relationships enable a comprehensive understanding of local regulatory requirements and changes, access to leading investigators, strong site connections, and accessible patient populations to deliver success for our clients within timelines and budgets."
CNS Managing Director Russ Neal commented:
"Early phase research in Australasia has seen incredible growth over the last 6-7 years and CNS is proud to be a significant part of this proven capability. As our clients have experienced success with us, we have often wished we had the international reach to continue supporting them.
"This truly complimentary association with Novotech now means that we are able to offer our clients access to Novotech's Asia-Pacific experience and expertise in later phase regional or global trials. On the other hand, Novotech clients can access our highly regarded global product development and regulatory affairs consultancy team, BioDesk, based out of Washington DC, London and Australia"
CNS COO and Executive Director Gabrielle McKee further added:
"CNS clients will also benefit from many of Novotech's strengths, including IT infrastructure and specialist functions such as legal, learning and development, marketing and analytics,. and particularly exciting, CNS and Novotech offer our clients one of the most experienced and knowledgeable biometrics teams in the region, with 70 staff in the combined unit."
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia-Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia-Pacific presence includes running clinical trials in all key regional markets, with a worldwide reach through the company's network of strategic partners.
About Clinical Network Services (CNS) - https://clinical.net.au/
Clinical Network Services (CNS) is an integrated service group focused on product development. Headquartered in Australia, with offices in New Zealand, the UK and the USA, CNS creates value for small to medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service, integrating BioDesk, an intelligent global product development and regulatory affairs consultancy, with its committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.
CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables it to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
Media Contact:
Susan Fitzpatrick-Napier
communications@novotech-cro.com
USA: +1 415 951 3228
AUS: +61 2 8218 2144
ASIA: +65 3159 3427Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 43 minutes ago.
↧
↧
Cricket Australia's next gen headlines Prime Minister's XI
Jack Edwards emerged as a star of the future by becoming the youngest centurion in Australia's one-day cup history this season.
Reported by Brisbane Times 35 minutes ago.
↧
Australian world title contender Wilson advances in Portugal
The 2018 world surfing title is now a race between two, Brazilian Gabriel Medina and Australia's Julian Wilson.
Reported by Brisbane Times 18 minutes ago.
↧
NAB boss regrets customers' loss of trust
National Australia Bank chief executive Andrew Thorburn says his bank hasn't had the care and respect for customers it should have.
Reported by SBS 3 minutes ago.
↧
Verdant Minerals completes environmental permitting for Ammaroo Phosphate Project
Verdant Minerals Ltd (ASX:VRM) has completed the environmental impact assessment process for its Ammaroo Phosphate Project in the Northern Territory. The company received approval of the project’s environmental impact assessment report from the Northern Territory Environment Protection Authority (NTEPA), marking the end of the environmental permitting process. Verdant is now focused on finalising native title mining agreements as well as obtaining mineral lease grants ahead of securing project development funding. Verdant managing director Chris Tziolis said this was a major milestone for the company and the Ammaroo project. He said: “The completion of the assessment process by the NTEPA provides Verdant with the regulatory baseline required to move the Ammaroo Project towards final mining authorisations and the attainment of statutory licences. “This marks the end of the most rigorous part of the approval and permitting process. “We will also now move on with the implementation and financing stage of the project, progressing toward a final investment decision.” READ: Verdant Minerals continues to progress Australia’s largest phosphate resource Ammaroo had already received Federal Government approval under the Environmental Protection and Biodiversity Conservation Act, as announced in June. The NTEPA has made further recommendations to inform the next phase of mining authorisation under the Northern Territory's Mining Management Act. It said that the proposal could be managed in a manner likely to meet NTEPA objectives and would avoid significant or unacceptable environmental impacts and risks. Overview of the environmental assessment and project authorisation process READ: Verdant Minerals progressing environmental impact assessment for Ammaroo Phosphate Project The company has completed a feasibility study for producing an initial 1 million tonnes per annum of phosphate rock concentrate, followed by a subsequent expansion to 2 million tonnes after year five. Ammaroo contains ultra-low cadmium rock, ideally suited as feedstock to produce phosphoric acid. The resource is shallow, free-digging, moderate grade phosphate ore resulting in very low mining costs. Verdant has developed a mine plan for 20 years of mining utilising less than 10% of the known resource. This is likely to expand to 50-plus years of operation. The regional exploration potential is significant and may underpin a major phosphate province.
Reported by Proactive Investors 14 minutes ago.
↧
↧
'If you want to worry about something ... this is it': Central banks, investors sound alarm
One troubling corner of the debt market has investors and the central banks of the UK and Australia raising red flags.
Reported by Sydney Morning Herald 3 minutes ago.
↧
New book feeds the annual obsession of Australia's tomato growers
A friend's mother recently told me that she couldn't take a holiday between now – when she is covering her tomato seedlings with sheets of plastic every night – and early autumn, when the last of her 100-plus plants will finally be spent.
Reported by Sydney Morning Herald 3 minutes ago.
↧
Insiders have been buying these ASX shares this week
Insiders have been buying Domain Holdings Australia Ltd (ASX:DHG) shares and two others this week...
Reported by Motley Fool 7 minutes ago.
↧
Man admits multiple rapes and month-long kidnap of UK backpacker in Australia
Marcus Allyn Keith Martin awaits sentencing for 'horrific and terrifying' assaults
Reported by Independent 5 hours ago.
↧
↧
Prince Harry Can't Stop Smiling As He Scales Sydney Harbour Bridge Without Meghan Markle
Prince Harry took his royal tour of Australia to new heights on Friday when he scaled the Sydney Harbour Bridge in order to place the Invictus Games flag atop the famous destination in Sydney. His ...
Reported by Access Hollywood 4 hours ago.
↧
Pakistan clinch Australia series with biggest ever Test win
Pakistan beat Australia by 373 runs in the second Test to claim a 1-0 series victory in Abu Dhabi and record their biggest Test win in terms of runs.
Reported by BBC Sport 5 hours ago.
↧
We have a hell of a lot to do on our batting - Paine
The Australia captain dismissed claims that his team had taken Abbas lightly and spent all their energy on working on methods to combat Pakistan's spinners
Reported by CricBuzz 5 hours ago.
↧
Siyata Mobile Receives $410,000 In Proceeds
MONTRÉAL, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (the "Company" or "Siyata") (TSX-V:SIM / OTCQX:SYATF) announces it has received $410,000 in proceeds from 1.3M options that were expiring in late September and October.*About Siyata*
A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.
Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.
On Behalf of the Board of Directors of:
*SIYATA MOBILE INC.*
Marc Seelenfreund
CEO and Chairman
*Investor Relations:*
Arlen Hansen
Kin Communications
1-866-684-6730
SIM@kincommunications.com
*Sales Department:*
Glenn Kennedy, VP Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Reported by GlobeNewswire 5 hours ago.
A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.
Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.
On Behalf of the Board of Directors of:
*SIYATA MOBILE INC.*
Marc Seelenfreund
CEO and Chairman
*Investor Relations:*
Arlen Hansen
Kin Communications
1-866-684-6730
SIM@kincommunications.com
*Sales Department:*
Glenn Kennedy, VP Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Reported by GlobeNewswire 5 hours ago.
↧
↧
Meghan Markle Reveals Her First Job--and It's Totally Relatable
Before she was the Duchess of Sussex or a star on Suits, Meghan Markle had a less glamorous gig. While speaking to a group of students at Macarthur Girls High School in Australia on...
Reported by E! Online 3 hours ago.
↧
Award Winning Engineers and Geoscientists Create a Better Future in BC, and Beyond
BURNABY, British Columbia, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Eight outstanding individuals and two projects are being honoured by Engineers and Geoscientists British Columbia at its Annual Conference in Vancouver, BC from October 19 – 20, 2018. This year’s recipients have truly made a difference in their respective professions, careers or communities. They are being honoured for exceptional professional achievement, outstanding service to the community and to professional associations or learned societies, distinctive accomplishments in their professional fields, and excellence in teaching.
BC’s engineers and geoscientists are explorers and problem solvers who lead the way in public safety, quality, and innovation. They are committed to improving and protecting the health and well-being of the people of this province every day.
The award recipients, their respective award category and city of residence are listed below:
*President’s Award* *Name* *City*
R.A. McLachlan Memorial Award Dr. Elizabeth Croft, P.Eng., FEC Clayton, Australia
C.J. Westerman Memorial Award Mr. Mike Miles, P.Geo. Victoria, BC
Meritorious Achievement Award Mr. Mike Wei, P.Eng. Victoria, BC
D.C. Lambert Professional Service Award Dr. Sheryl Staub-French, P.Eng. Vancouver, BC
Teaching Award of Excellence Dr. Bradley Buckham, P.Eng. Victoria, BC
Teaching Award of Excellence Mr. David Nelles, P.Geo. Victoria, BC
Community Service Award Mr. David Desrochers, P.Eng. North Vancouver, BC
Young Professional Award Mr. Nathan Ozog, P.Eng. Vancouver, BC
Engineers and Geoscientists BC’s Sustainability Award recognizes a project that demonstrates a commitment to, and understanding of the concept of sustainability, while the Environmental Award recognizes a project that exemplifies exceptional environmental protection or environmental enhancement.
*Project Award* *Project*
Sustainability Award UBC Aquatic Centre Project
Submitted by AME Consulting Group Ltd.
Environmental Award Rock Bay Remediation Project
Submitted by SNC-Lavalin
Engineers and Geoscientists British Columbia is the regulatory and licensing body for the engineering and geoscience professions in BC. To protect the public, we maintain robust standards for entry to the professions, and comprehensive regulatory tools to support engineers and geoscientists in meeting professional and ethical obligations.
Note to Editors/News Directors:
Award citations, photos, and additional information is available by contacting:
Megan Archibald
Director, Communications and Stakeholder Engagement
Engineers and Geoscientists BC
Email: marchibald@egbc.ca
Mobile: 604-839-1595
Reported by GlobeNewswire 5 hours ago.
BC’s engineers and geoscientists are explorers and problem solvers who lead the way in public safety, quality, and innovation. They are committed to improving and protecting the health and well-being of the people of this province every day.
The award recipients, their respective award category and city of residence are listed below:
*President’s Award* *Name* *City*
R.A. McLachlan Memorial Award Dr. Elizabeth Croft, P.Eng., FEC Clayton, Australia
C.J. Westerman Memorial Award Mr. Mike Miles, P.Geo. Victoria, BC
Meritorious Achievement Award Mr. Mike Wei, P.Eng. Victoria, BC
D.C. Lambert Professional Service Award Dr. Sheryl Staub-French, P.Eng. Vancouver, BC
Teaching Award of Excellence Dr. Bradley Buckham, P.Eng. Victoria, BC
Teaching Award of Excellence Mr. David Nelles, P.Geo. Victoria, BC
Community Service Award Mr. David Desrochers, P.Eng. North Vancouver, BC
Young Professional Award Mr. Nathan Ozog, P.Eng. Vancouver, BC
Engineers and Geoscientists BC’s Sustainability Award recognizes a project that demonstrates a commitment to, and understanding of the concept of sustainability, while the Environmental Award recognizes a project that exemplifies exceptional environmental protection or environmental enhancement.
*Project Award* *Project*
Sustainability Award UBC Aquatic Centre Project
Submitted by AME Consulting Group Ltd.
Environmental Award Rock Bay Remediation Project
Submitted by SNC-Lavalin
Engineers and Geoscientists British Columbia is the regulatory and licensing body for the engineering and geoscience professions in BC. To protect the public, we maintain robust standards for entry to the professions, and comprehensive regulatory tools to support engineers and geoscientists in meeting professional and ethical obligations.
Note to Editors/News Directors:
Award citations, photos, and additional information is available by contacting:
Megan Archibald
Director, Communications and Stakeholder Engagement
Engineers and Geoscientists BC
Email: marchibald@egbc.ca
Mobile: 604-839-1595
Reported by GlobeNewswire 5 hours ago.
↧
Fractures Releases New Song 'Sculptures,' Signs With Fader Label
The Fader announced today (Oct. 19) the signing of singer/songwriter Fractures, the stage name of Melbourne, Australia-based Mark Zito, to its Fader...
Reported by Billboard.com 3 hours ago.
↧
